Psychostimulants for depression.

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Trials

Background:

• Depression is a prevalent, debilitating, and costly condition with suboptimal treatment outcomes.
• Current first-line antidepressant therapies present challenges for moderate to severe depression.
• Psychostimulants (PS) have been investigated for depression treatment, necessitating a systematic review.

Purpose of the Study:

• To systematically evaluate the effectiveness of psychostimulants (PS) in treating depression.
• To assess the adverse events associated with PS use in depression.

Main Methods:

• A systematic search of multiple databases (e.g., Cochrane, MEDLINE, EMBASE) was conducted.
• Included were randomized controlled trials (RCTs) of adults diagnosed with depression, comparing PS to placebo or active treatments.
• Data extraction and quality assessment were performed independently; meta-analysis was used for comparable trials.

Main Results:

• Twenty-four RCTs of generally low quality were identified, evaluating five different PS.
• Oral PS as monotherapy significantly reduced short-term depressive symptoms compared to placebo (SMD -0.87).
• PS were generally well-tolerated in the short term, but tolerance and dependence were under-evaluated.

Conclusions:

• Evidence suggests short-term efficacy of PS in reducing depression symptoms, though clinical significance remains uncertain.
• Larger, high-quality trials with extended follow-up are required.
• Further research should investigate optimal PS, clinical situations, and long-term safety profiles.